Atlassian Co. (NASDAQ:TEAM – Get Free Report) President Anutthara Bharadwaj sold 760 shares of Atlassian stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $163.11, for a total value of $123,963.60. Following the completion of the sale, the president now owns 143,966 shares of the company’s stock, valued at $23,482,294.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Anutthara Bharadwaj also recently made the following trade(s):
- On Friday, July 19th, Anutthara Bharadwaj sold 760 shares of Atlassian stock. The stock was sold at an average price of $175.00, for a total value of $133,000.00.
Atlassian Stock Performance
NASDAQ TEAM opened at $162.62 on Wednesday. The company has a 50-day simple moving average of $161.22 and a two-hundred day simple moving average of $174.62. Atlassian Co. has a 12-month low of $135.29 and a 12-month high of $258.69. The firm has a market cap of $42.33 billion, a price-to-earnings ratio of -258.13 and a beta of 0.73. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.95.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in TEAM. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Atlassian during the 2nd quarter valued at $12,846,000. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Atlassian during the second quarter worth about $462,000. Sanctuary Advisors LLC bought a new stake in shares of Atlassian in the second quarter worth about $1,022,000. New Century Financial Group LLC purchased a new position in Atlassian during the 2nd quarter valued at about $397,000. Finally, Truist Financial Corp raised its position in Atlassian by 2.5% during the 2nd quarter. Truist Financial Corp now owns 84,358 shares of the technology company’s stock valued at $14,921,000 after purchasing an additional 2,050 shares during the last quarter. 93.03% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on TEAM. BMO Capital Markets cut their price objective on shares of Atlassian from $220.00 to $177.00 and set a “market perform” rating on the stock in a report on Friday, August 2nd. Scotiabank cut their target price on shares of Atlassian from $210.00 to $175.00 and set a “sector perform” rating for the company in a research report on Friday, August 2nd. Piper Sandler upgraded Atlassian from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $200.00 to $225.00 in a research note on Tuesday, July 2nd. Baird R W downgraded shares of Atlassian from a “strong-buy” rating to a “hold” rating in a report on Friday, August 2nd. Finally, The Goldman Sachs Group upgraded shares of Atlassian from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $200.00 to $230.00 in a research report on Friday, August 2nd. Ten analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Atlassian has a consensus rating of “Moderate Buy” and a consensus target price of $217.69.
Read Our Latest Stock Report on Atlassian
Atlassian Company Profile
Atlassian Corporation, through its subsidiaries, designs, develops, licenses, and maintains various software products worldwide. Its product portfolio includes Jira Software and Jira Work Management, a project management system that connects technical and business teams so they can better plan, organize, track and manage their work and projects; Confluence, a connected workspace that organizes knowledge across all teams to move work forward; and Trello, a collaboration and organization product that captures and adds structure to fluid and fast-forming work for teams.
See Also
- Five stocks we like better than Atlassian
- Options Trading – Understanding Strike Price
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Atlassian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlassian and related companies with MarketBeat.com's FREE daily email newsletter.